Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA-CD3 CrossMAb
- Development stage
- Preclinical
- Lead developer
- Roche
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
BCMA-CD3 CrossMAb refers to a bispecific antibody architecture that simultaneously targets B-cell maturation antigen (BCMA) and the CD3 epsilon subunit of the T-cell receptor complex. Utilizing the CrossMAb technology—which involves the crossover of antibody domains to ensure correct light-chain association—this modality functions as a T-cell engager. It facilitates the recruitment and activation of cytotoxic T cells to specifically eliminate BCMA-expressing malignant plasma cells. ProMab Biotechnologies has developed humanized versions of this antibody (using the 4C8A clone), including univalent and bivalent CrossMAb designs. In preclinical studies, these antibodies demonstrated high affinity for BCMA-positive cells, induced significant IFN-gamma secretion, and showed potent dose-dependent cytotoxic activity in multiple myeloma xenograft models.
- Other names
- hBCMA-CD3 CrossMAbhBCMA-CD-3 CrossMAbhBCMA-CD 3 CrossMAbhumanized BCMA-CD3 CrossMAbBCMA-CD3 CrossMABBCMA-CD-3 CrossMABBCMA-CD 3 CrossMAB
02
Targets
BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on BCMA-CD3 CrossMAb.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA-CD3 CrossMAb.